The BAMM2 (BRAF Autophagy MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAFV600E/K Melanoma with elevated LDH

Brief description of study

Hydroxychloroquine inhibits a process called autophagy which helps tumors survive. The purpose of the study is to see how well different treatments work when hydroxychloroquine is added to dabrafenib and trametinib in advanced BRAFV600E/K melanoma with elevated lactate dehydrogenase (LDH). We want to know the best overall response rate by treatment arm and evaluate the adverse event rate by treatment arm.


Clinical Study Identifier: s21-01037
Principal Investigator: Janice Mehnert.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.